The period of development of a new drug averages 10-15 years from initial invention of the chemical structure to approval for general use. In the US, the current cost can approach 100 million dollars, while elsewhere it can be approximately 15-20 million pounds sterling. Two main stages are involved in drug development (Figure 1 ): the preclinical stage comprises chemistry (synthesis, purification, patenting), pharmacology, pharmacokinetics and toxicology in animals and pharmaceutical development of dosage forms; the clinical stage includes four phases which embrace all studies done in man ( Figure 1 ).
The major aim of drug development is a safe-and effective product. If a drug causes many minor side effects, or one serious one, development will probably be stopped unless the drug is of unique clinical benefit. However, for some drugs unusual serious adverse drug reactions (ADR) have been identified for the first time after marketing, e.g. benoxaprofen (Opren), indomethacin slow release', and zimel-dine2. In these cases the incidence ofthe ADR was so low, about 1:10 000-1:100 000 patients treated, that it was impossible to identify even in the large-scale clinical trials3 done before marketing; it follows that this type of rare ADR cannot be avoided even with extensive testing before marketing, and this must be accepted if Regulations governing administration of a NCE to man In most European countries and the USA4, approval of an Investigation of New Drugs Notice (IND) by the regulatory authorities is required for studies of the drug in phase I; in some countries the filing of a specific IND is also required for clinical trials in patients in phases II and m. An IND consists of extensive pharmacological and toxicological data from animals. For development of drugs in the USA, there has been an increasing trend to begin clinical trials in other countries before filing an IND with the Food and Drug Administration (FDA)5. In the UK, no official approval is needed before a NCE can be given to normal subjects for the first time; absence of official regulation has been debated in the lay press and on television, and the issue of drug studies in normal subjects is under review by a Royal College of Physicians working party. In North America and Europe, data for the NCE will generally have been obtained in normal subjects before it is tested in small numbers of patients. However, in the UK only animal data are required before a drug can be given to patients, but most pharmaceutical companies would test their NCE in normal subjects prior to studies in patients. In the UK, the DHSS allows two ways for a pharmaceutical company to apply for permission to give a NCE to patients6. If application is made for a clinical trial certificate (CTC), then all original data available (animal data and results of studies in normal subjects) are submitted to the DHSS. Application for a CTC takes a longer time for approval than the alternative, which is application for exemption from the CTC (called the CTX scheme). In a CTX application, only summaries of the data (only animal data) are required by the DHSS, which must reach a decision within 35 days of receipt of the CTX application, although the DHSS may invoke an additional 28 days, where necessary. However, if the CTX scheme is used, all subsequent protocols for clinical trials have to be approved by the DHSS. The DHSS may exclude certain drugs from the CTX scheme, e.g.
histamine H2-antagonists. If the NCE shows safety and efficacy in clinical trials, then a 'new drug application' (NDA) may be made to the USA or European regulatory authorities (Product Licence Application in the UK) who may then issue a licence to market the drug.
Pre-clinical data requirements before administration of a NCE to man Much information is needed before a single dose of a NCE can be given to normal subjects or patients7 10. The necessary pharmacodynamic profile includes screening of general actions of the drug on body systems to determine safety and assist in dose prediction for man by comparison with similar drugs already used in humans (if any). Similar principles underlie the special pharmacology of a compound; for example, a new loop diuretic would be studied in various species for natriuretic, chloriuretic, and uricosuric actions and effects on purine metabolism, carbonic anhydrase activity and glucose metabolism. Metabolic and pharmacokinetic studies of the drug would be done in several animal species; including studies of the disposition of radioactively labelled drug in blood and excreta and by whole body autoradiography to detect tissue localization, e.g. in uveal tract and gonads. In the UK, toxicity studies for CTX and CTC applications have to be carried out using the same route of administration as that to be used in man. The duration of toxicity testing depends on the proposed length of administration, but single-dose studies in at least 2 mammalian species and repeated dose studies of 14-180 days' duration in 2 species, at least one of which must be non-rodent (usually rat and dog respectively), are required as a minimum. Under the CTX scheme in the UK, reproduction toxicity tests and long-term carcinogenicity studies can be omitted initially, but tests for mutagenicity such as the Ames test or genotoxicity such as impairment of DNA repair in yeasts are usually required. The chemical purity of the drug preparation must be ensured before administration to man or to animals and pharmaceutical tests must show that the formulation is acceptable, e.g. the drug is stable, undergoes dissolution and will not cause haemolysis when injected.
Choice offirst dose in man In spite of the large amount of animal data, extrapolation from this to man for calculation of the first dose is a problem11. The starting dose in phase I is usually chosen as the lowest of the following amounts measured in the most sensitive animal species and calculated for a 70 kg man: (1) 1/100 of the effective dose (ED=smallest dose to, evoke a pharmacological response) in the most sensitive animal species; (2) 1/60 of the ED50 (ED50=the dose producing a response in 50%/0 of the test population of animals); (3) 1/600 of the LDSO in the most sensitive species (LD50=lethal dose in 50% of the test population of animals)9.
Subsequent dose increases vary, but obviously the larger the increments the greater the risk of moving from therapeutic to toxic points along the doseresponse curve; common increments are 33, 50 or 100% ofthe previous test dose'2.
Phase I or human pharmacology studies Phase I studies are done in order to obtain information about the safety and actions of the NCE (pharmacodynamics) as well as its absorption, distribution, metabolism and elimination (pharmacokinetics) after single and multiple doses in normal subjects in whom there are no complicating factors resulting from disease. An approximate dose for use in patients may be found from phase I studies.
Therefore, the first study of NCE in man is a dose-tolerance study to define a dose range and to assess safety in a minimum number of subjects at each dose level92"3. If possible, an aqueous solution of the NCE is used because this is usually quicker and better absorbed than a tablet or capsule. The oral route of administration is mostly used first because it provides the metabolic defences of gut wall and hepatic metabolism and allows a slower rate of entry into the bloodstream than the intravenous route". If the drug is active by mouth, the next study would be a dose-tolerance intravenous study so that a safe, intravenous dose can be chosen against which blood concentrations of the NCE can be compared after oral dosing to obtain a measure of the absolute bioavailability'5"l6. The advantage of the intravenous route is that variation between subjects is less for the amount of active drug entering the bloodstream and the rate of entry ofthe drug can be carefully controlled. Pharmacodynamic studies with larger numbers of subjects can later be done to obtain an accurate detailed pharmacodynamic profile for the drug. Measurements of drug concentrations in body fluids'7"5 are included in pharmacodynamic studies so that correlation of drug pharmacokinetics can be made with drug effects. Correlation between plasma drug concentrations and pharmacodynamic effects suggest that the NCE is an active drug.
Even with modern, specific, sensitive drug measurement techniques, a study of the absorption, distribution in blood and excretion of radiolabelled (usually carbon 14) drug may be needed to define the metabolic profile of the drug (sometimes called a 'mass balance' study)'3" 9. For safety, the minimum number of males aged above 40 years should be studied, radiochemical purity of the compound should be more than 98%, and the total-body radiation dose and maximum single organ dose must be within the amounts permitted by the WHO.
The term 'phase I' is misleading because human pharmacology studies continue throughout the whole development ofdrugs. Included in later phases of development are drug interaction studies20 (e.g. with alcohol or oral anticoagulants), pharmacokinetics in the elderly or patients with kidney and liver disease and specific studies to evaluate indirect or unwanted drug effects, e.g. nitrosamine formation in the stomach after acid secretion inhibitors21 or the effect of antidepressants on the heart22'23.
Phase II or early studies in patients24
Phase II aims to give information about the appropriate dose range, drug effects or disease processes and side effects. Efficacy cannot be fully evaluated in phase II if the studies are open and/or uncontrolled, as commonly occurs; however, efficacy can be measured if double-blind, placebo-controlled studies are performed, and this is the usual practice in the USA.
There are advantages in beginning studies of a NCE as early as possible in patients in order to obtain early confirmation of efficacy and safety25. These studies usually take 1-2 years (Figure 1 ). In phase II, the duration of treatment allowed depends upon the animal toxicology data available, but most studies allow treatment for 28-42 days. The patients should be in hospital during the first treatment period but can be treated as outpatients thereafter. Most pharmaceutical companies would require good drug safety and good indications of efficacy in the appropriate dose range26 before deciding to continue development into phase III.
Phase III This phase takes approximately 3-4 years. The aims are to confirm the efficacy, the appropriate dose range and safety. An appropriate dose range must have been identified in phase II, as not more than two or three dose levels ought to be tested in phase HI. These studies are usually double-blind controlled trials comparing the NCE with placebo and with drugs recognized -for treatment of the disorder under investigation.
In this phase the multicentre clinical trials are done with at least 20-30 patients in each treatment group; if two dose levels of the NCE, a placebo and an established drug are used for compaison, the study will include a large number of patients. However, the exact numbers of patients required are determined by the magnitude of the anticipated response to the NCE or to drugs involved, and the power of the statistical tests chosen to analyse the results. In the case of drugs for chronic conditions, e.g. hypertension or rheumatoid arthritis, it is usual practice to include data for at least 100 patients treated continually with the drug for at least one year in order to obtain adequate safety infor-mation26 27 . If the NCE shows good efficacy, better than placebo and better or at least as good as the comparative drug, and the NCE causes no more or less ADR than the comparative drug, then a 'NDA' (New Drug Application) is submitted to the regulatory authorities. The NDA or product licence application can go up to 20-60 volumes. As sme regulatory authorities (US and Canada) require all original material generated in clinical studies, the size of a NDA submission can be enormous. The regulatory authorities take 6-24 months, depending upon country, to either approve or reject the NDA; they may also in the intervening period ask for additional information.
The clinical trial programme is continued even after submission of the NDA. If the NDA is approved the NCE is considered to be a drug and is marketed.
Placebo and comparative drugs in clinical trials
Placebos are used to distinguish between effects resulting from drug action (efficacious or side effects) and those due to nonspecific factors or chance2". It is generally thought that a placebo response rate of about 35% can be anticipated for most disease processes29. Even if a NCE is compared with an established drug, inclusion of a placebo in the trial is needed to be certain that any disease response to either the NCE or the established drug is due to a drug effect and not to a nonspecific influence28. This introduces the ethical problem of the use of placebos, for example in evaluating con-traceptives30 and in-life-threatening circumstances in which it is impossible to contemplate the use of a placebo.
Phase IV Critics of the pharmaceutical industry often state that the studies during this phase are marketorientated, but there is evidence that the pharmaceutical industry has a major role in providing information about newly introduced drugs and in educating physicians3"'32. However, there are often some basic scientific questions that still need to be answered; for example, comparing efficacy with other established drugs and looking at more effective and convenient dosage regimens, e.g. twice daily instead of three or four times daily33.
Post-marketing purveillance studies are becoming of increasing importance34'35 and are aimed at detecting as early as possible any ADR to new drugs; new ADRs are more likely to become apparent when a drug is prescribed on a broader basis than that involved during phases I to 11136. Conclusion This paper has described only the development of conventional drugs for prescription by doctors. However, it is our belief that all drugs, including homeopathic and herbal treatments, should be tested along similar lines in order to ensure safety and efficacy. In the UK the British Medical Association working party is considering this problem in the use of alternatives to conventional drugs.
